Images List Premium Download Classic

Obesity

Obesity-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
New thienopyrimidine derivatives as nik inhibitors
October 18, 2018 - N°20180298032

The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of nf-κb-inducing kinase (nik—also known as map3k14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, to ...
Triazole derivativesas p2y14 receptor antagonists
October 18, 2018 - N°20180297981

Described are compounds, which are antagonists of the p2y14 receptor, for example, a compound of formula (i) in which ring a, r1, r2, r3, and n are as described herein. Also provided are dendron conjugates comprising the compounds, and methods of using the compounds, including a method of treating a disorder, such as inflammation, diabetes, insulin resistance, hyperglycemia, a ...
Methods and compositions for treatment of metabolic disorders
October 18, 2018 - N°20180296671

The present invention relates to the discovery that increases in invariant nkt cell (inkt) number and/or activity can reduce the incidence or severity of metabolic disorders such as obesity and diabetes. The invention accordingly features methods, kits, and compositions for the treatment of such metabolic disorders by administration of a composition capable of increasing inkt activity..
Obesity Patent Pack
Download 316+ patent application PDFs
Obesity Patent Applications
Download 316+ Obesity-related PDFs
For professional research & prior art discovery
inventor
  • 316+ full patent PDF documents of Obesity-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Use of akkermansia muciniphila for treating inflammatory conditions
October 18, 2018 - N°20180296613

The invention relates to use of akkermansia muciniphila, a mucin-degrading bacterial species found in the human gut, for treating undesirable inflammatory activity not caused by any metabolic disorder and/or obesity, especially for example undesirable airway inflammatory activity as seen with asthma.. .
Compositions and methods for diagnosis and treatment of metabolic syndrome
October 18, 2018 - N°20180296518

Compositions including an odd chain fatty acid, and salts and derivatives thereof, and methods for metabolic syndrome treatment and prophylaxis are provided, including compositions and methods for treating diabetes, obesity, hyperferritinemia, elevated insulin, glucose intolerance, dyslipidemia and related conditions. Methods for the diagnosis and monitoring of metabolic syndrome are also provided..
Electroporation for obesity or diabetes treatment
October 18, 2018 - N°20180296264

Endolumenal devices and methods can be used for the treatment of health conditions including obesity and diabetes. In some embodiments, the methods and systems provided herein can cause weight loss or control diabetes by reducing the caloric absorption of an individual.
Obesity Patent Pack
Download 316+ patent application PDFs
Obesity Patent Applications
Download 316+ Obesity-related PDFs
For professional research & prior art discovery
inventor
  • 316+ full patent PDF documents of Obesity-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Cell-permeable (cp)-delta socs3 recombinant protein and uses thereof
October 11, 2018 - N°20180291073

The present invention is related to development of the improved cell-permeable (cp)-Δsocs3 recombinant protein which disrupt the interaction of leptin receptor (obr) and suppressor of cytokine signaling 3 (socs3), as protein-based anti-obesity or anti-diabetes agent by utilizing the platform technology for macromolecule intracellular transduction.. .
Aryl acylsulfonamides as blt1 antagonists
October 11, 2018 - N°20180291017

Novel compounds of the structural formula (i), and the pharmaceutically acceptable salts thereof, are antagonists of leukotriene b4 receptor 1 (blt1) and may be useful in the treatment, prevention and suppression of diseases mediated by the leukotriene b4 receptor 1 (blt1). The compounds of the present invention may be useful in the treatment of type 2 diabetes mellitus, insulin resistance, hyperglycemia, dyslipidemia, lipid ...
Compositions and methods for the treatment of metabolic and related disorders
October 11, 2018 - N°20180291013

The present invention relates to treatment and/or prevention of one or more metabolic disorders utilizing fatostatin a and/or a derivative and/or analog thereof. In other aspects, the compound for treatment and/or prevention of one or more metabolic disorders utilizes an a-b-c tripartite structure, wherein a, b, and c are identical or non-identical structures and are described ...
Monocarboxylate transport modulators and uses thereof
October 11, 2018 - N°20180290978

The invention generally relates to the field of monocarboxylate transport modulators, e.g., monocarboxylate transport inhibitors, and more particularly to new substituted-quinolone compounds, the synthesis and use of these compounds and their pharmaceutical compositions, e.g., in treating, modulating, forestalling and/or reducing physiological conditions associated with monocarboxylate transport activity such as in treating cancer and other neoplastic disorders, inflammatory ...
Identification of cyclic peptide agonists of galanin receptor 2 and 3 guided by spexin solution structure
October 11, 2018 - N°20180289766

Cyclic peptide agonists toward human galanin receptor 2 (galr2) and galanin receptor 3 (galr3) based on hidden conformation of spexin solution structure for galr2 and galr3-related and spexin-deficient disorders are designed and synthesized. Lh101, lh102, and lh101 (ac) are potent spexin analogs with prolonged action, which can be used in the treatment of galr2 and galr3-related diseases and spexin-deficient disorders, ...
Treatment of adipocytes
October 11, 2018 - N°20180289707

The present disclosure provides compositions comprising a lyn kinase activator and trpm8 agonist, and to methods of: reducing blood glucose levels, weight gain, or fat depot levels; treating metabolic syndrome, syndrome x, obesity, prediabetes, type ii diabetes, type i diabetes; treating hypercholesterolemia, hypertension, coronary heart disease, diabetic neuropathy, lipodystrophy, diabetic retinopathy, erectile dysfunction, kidney disease, dyslipidemia, dyslipoproteinemia, a peroxisome proliferator ...
Flavonolignans for treatment of autoimmune inflammatory diseases
October 11, 2018 - N°20180289666

A method for reducing abnormalities in lipid metabolism and for reducing inflammation in a subject suffering from an autoimmune inflammatory disease accompanied by abnormalities in lipid metabolism includes administering an effective amount of a flavonolignan to the subject. The subject may additionally suffer from a liver disease, obesity, hypertension, diabetes mellitus or a metabolic syndrome.
Obesity Patent Pack
Download 316+ patent application PDFs
Obesity Patent Applications
Download 316+ Obesity-related PDFs
For professional research & prior art discovery
inventor
  • 316+ full patent PDF documents of Obesity-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Maternal vitamin b6 administration for the prevention of increased adiposity, overweight or obesity in the ...
October 04, 2018 - N°20180280369

The present invention generally relates to the early prevention of overweight, obesity, excessive fat accumulation and/or associated metabolic disorders in infants or children. For example, the present invention relates to the prevention of overweight, obesity, excessive fat accumulation and/or associated metabolic disorders in infants or children through appropriate nutrition for women desiring to get pregnant and/or during ...
Antibacterial and protective bacteriophage formulations and methods for making and using them
San Diego State University (sdsu) Foundation Dba San Diego State University Research Foundation
September 27, 2018 - N°20180273910

Provided are compositions and methods for treating, ameliorating and preventing infections, disorders and conditions in mammals, including genetically-predisposed and chronic disorders, where a microbial or bacterial flora is at least one causative or symptom-producing factor. Provided are compositions and methods used to treat, prevent or ameliorate an infection, for example, an infection in the gastrointestinal tract, or bowel.
Intragastric device
Obalon Therapeutics, Inc.
September 27, 2018 - N°20180272113

Devices and methods for treating obesity are provided. More particularly, intragastric devices and methods of fabricating, deploying, inflating, monitoring, and retrieving the same are provided..
Composition for preventing or treating menopausal disorders, containing tetragonia tetragonoides (pall.) kuntze extract
Korea Institute Of Oriental Medicine
September 27, 2018 - N°20180271923

The present invention relates to: a pharmaceutical composition for preventing or treating menopausal disorders, containing a tetragonia tetragonoides (pall.) kuntze extract or a fraction thereof; a method for preventing or treating menopausal disorders, comprising a step of administering the pharmaceutical composition; and a food composition containing the extract or a fraction thereof. The tetragonia tetragonoides (pall.) kuntze extract of the ...
Compositions and methods for white to beige adipogenesis
September 27, 2018 - N°20180271867

Disclosed herein are compositions and methods for transitioning or converting a white adipocyte to a beige adipocyte. The compositions and methods may be used in the treatment of obesity.
Metap2 inhibitors and methods of treating obesity
Syndevrx, Inc.
September 27, 2018 - N°20180271856

The present invention relates to modified or polymer conjugated metap2 inhibitors. The present invention also relates to methods of preventing, inducing, causing or increasing weight loss, treating obesity and/or treating metabolic syndrome utilizing the modified or polymer conjugated metap2 inhibitors.
Vitamin d3 derivatives and pharmaceutical use thereof
National University Corporation Tokyo University Of Agriculture And Technology
September 20, 2018 - N°20180265463

The present invention relates to vitamin d3 derivatives of the following formula, wherein each symbol has the same meaning as defined herein, and pharmaceutical or medical use thereof for treating metabolic disease, liver disease, obesity, diabetes, cardiovascular disease, or cancer in a patient in need thereof.. .
Cyclopropylmethanamines as selective 5-ht(2c) receptor agonists
The Board Of Trustees Of The University Of Illinois
September 20, 2018 - N°20180265453

Disclosed are 2-phenyl-cyclopropylmethanamines which are selective 5-ht(2c) receptor agonists and are used in the treatments of diseases and conditions wherein modulation of 5-ht(2c) receptors provides a benefit, such as obesity and psychiatric disorders.. .
Loading